Ka Hye In, Mun Se Hwan, Han Sora, Yang Young
Research Institute of Women's Health, Sookmyung Women's University, Seoul, 04312, Republic of Korea.
Oncol Res. 2025 Feb 28;33(3):519-531. doi: 10.32604/or.2024.056860. eCollection 2025.
Osteosarcoma is a bone malignancy characterized by strong invasiveness and rapid disease progression. The tumor microenvironment of osteosarcoma contains various types of immune cells, including myeloid-derived suppressor cells, macrophages, T cells, and B cells. Imbalances of these immune cells can promote the proliferation and metastasis of osteosarcoma. Recent studies have indicated a substantial increase in the levels of myeloid-derived suppressor cells, an immune cell associated with immunosuppressive and pro-cancer effects, in the peripheral blood of patients with osteosarcoma. Moreover, the levels of the pro-inflammatory cytokine interleukin 18 are positively correlated with those of myeloid-derived suppressor cells in the peripheral blood of animal models of osteosarcoma. In this review, we explore the function of myeloid-derived suppressor cells in osteosarcoma based on the clinical diagnoses of patients with osteosarcoma and discuss future therapeutic approaches for targeting osteosarcoma. Targeting myeloid-derived suppressor cells represents a promising approach to improving the prognosis and survival rates of patients with osteosarcoma.
骨肉瘤是一种具有强烈侵袭性和快速疾病进展特征的骨恶性肿瘤。骨肉瘤的肿瘤微环境包含多种类型的免疫细胞，包括髓源性抑制细胞、巨噬细胞、T细胞和B细胞。这些免疫细胞的失衡可促进骨肉瘤的增殖和转移。最近的研究表明，在骨肉瘤患者的外周血中，髓源性抑制细胞（一种与免疫抑制和促癌作用相关的免疫细胞）的水平大幅增加。此外，在骨肉瘤动物模型的外周血中，促炎细胞因子白细胞介素18的水平与髓源性抑制细胞的水平呈正相关。在这篇综述中，我们基于骨肉瘤患者的临床诊断探讨髓源性抑制细胞在骨肉瘤中的作用，并讨论未来针对骨肉瘤的治疗方法。靶向髓源性抑制细胞是一种有望改善骨肉瘤患者预后和生存率的方法。
